SPARTANBURG COMMUNITY CLINICAL ONCOLOGY PROGRAM

斯帕坦堡社区临床肿瘤学计划

• 批准号: 3557530
• 负责人: James D Bearden
• 金额: $ 18.49万
• 依托单位: SPARTANBURG REGIONAL MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1983
• 资助国家: 美国
• 起止时间: 1983-09-01 至 1996-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3557530
• 关键词: 13 cis retinoate; Hodgkin's disease; acute leukemia; acute lymphocytic leukemia; adenocarcinoma; antineoplastics; behavioral medicine; biomarker; bladder neoplasm; bleomycin; breast neoplasms; cancer information system; cancer prevention; cancer registry /resource; cancer rehabilitation /care; cancer risk; cervix neoplasms; chemoprevention; cis platinum compound; clinical trials; colorectal neoplasms; combination chemotherapy; community health services; continuing education; cooperative study; cyclophosphamide; cystectomy; cytogenetics; cytosine arabinoside; dacarbazine; daunorubicin; doxorubicin; early diagnosis; etoposide; flow cytometry; fluorouracil; germ cell neoplasms; head /neck neoplasm; human subject; human therapy evaluation; hydroxyurea; ifosfamide; interferons; leucovorin; levamisole; lomustine; lung neoplasms; lymphoma; mammography; mechlorethamine; melanoma; methotrexate; multiple myeloma; neoplasm /cancer chemotherapy; neoplasm /cancer diagnosis; neoplasm /cancer education; neoplasm /cancer genetics; neoplasm /cancer immunotherapy; neoplasm /cancer nutrition therapy; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; neoplasm /cancer therapy; nutrition related tag; oral leukoplakia; ovary neoplasms; paclitaxel; pancreas neoplasms; patient /disease registry; patient care management; peptide hormone analog; pharmacy administration; prednisone; primary care physician; procarbazine; prostate neoplasms; quality of life; regional medical planning; relaxation; small cell lung cancer; smoking cessation; tamoxifen; testis neoplasms; tocopherols; trimetrexate; vincristine

The Spartanburg Community Clinical Oncology Program (SCCOP) has been an enthusiastic participant in the CCOP program since its inception. Since 1983 SCCOP has accrued greater than 10% of all newly diagnosed cancer patients in our regional tumor registry to cancer treatment protocols with data of high quality and low cost per accrual in this rural CCOP. The average accrual per year of 102 compares favorably with the average yearly treatment accrual CCOP wide of 86 as stated in the RFA. The SCCOP accrued 100 subjects to cancer control protocols in FY-06, equivalent to the average accrual CCOP wide of 109.6 subjects per year as stated in the RFA. SCCOP believes that participation in NCI approved cancer treatment and cancer control protocol activities is an ideal way to bring state-of-the- art cancer treatment and cancer control research to members of our community and involve a wider segment of our community in such activities. This participation will transfer newly developed technology in cancer prevention, early detection, treatment, patient management, rehabilitation and continuing care to our community in an accelerated fashion and correspondingly reduce cancer incidence, morbidity and mortality. The goals of the SCCOP for this grant period are to maintain and expand our cancer treatment accruals and to develop a comprehensive cancer control trials program. This will be accomplished by enlisting a larger number of subspecialty investigators (ENT, urology, surgical oncology, gynecology) in cancer treatment and cancer control activities, and encompassing both the family practice residency program at Spartanburg Regional Medical Center and private practice primary care physicians in cancer control activities. The SCCOP will continue to affiliate with SWOG, CCWFU, NSABP, and MDACC as research bases. The grant will support three full-time equivalents for data management. The consortium hospitals, as a measure of their commitment to the CCOP program, are providing significant funding for one FTE (secretary/data manager) and additional funds for travel and cancer control data management activities. The SCCOP enthusiastically recompetes at this time for continued funding for an activity which has proven extremely rewarding for this community.

斯巴达堡社区临床肿瘤学计划 (SCCOP) 自 CCOP 计划启动以来，一直是该计划的热心参与者。 自从 1983 年 SCCOP 占所有新诊断癌症的 10% 以上 我们区域肿瘤登记处的患者接受癌症治疗方案 该农村 CCOP 中的数据质量高、单位应计成本低。 这 每年平均应计收益为 102，与平均年收益相比相当不错 如 RFA 中所述，治疗应计 CCOP 为 86。 SCCOP 在 2006 财年招募了 100 名癌症控制方案受试者， 相当于每年 109.6 个科目的平均应计 CCOP RFA 中指出。 SCCOP 认为参与 NCI 批准的癌症治疗和 癌症控制协议活动是实现最新状态的理想方式 为我们的成员提供艺术癌症治疗和癌症控制研究 社区并让我们社区更广泛的部分参与此类活动。 此次参与将转让新开发的癌症技术 预防、早期发现、治疗、患者管理、康复 并以加速的方式继续关心我们的社区 相应地降低癌症的发病率、发病率和死亡率。 SCCOP 在本资助期内的目标是维持和扩大我们的 癌症治疗累积并制定全面的癌症控制 试验计划。 这将通过招募更多的人来实现 亚专业研究人员（耳鼻喉科、泌尿科、肿瘤外科、妇科） 癌症治疗和癌症控制活动，包括 斯帕坦堡地区医疗中心的家庭实践住院医师计划 和私人执业初级保健医生从事癌症控制活动。 SCCOP 将继续与 SWOG、CCWFU、NSABP 和 MDACC 合作 研究基地。 这笔赠款将支持三名全职人员 数据管理。 联合医院作为其实力的衡量标准 对 CCOP 计划的承诺，正在为一项活动提供大量资金 FTE（秘书/数据经理）以及用于旅行和癌症的额外资金 控制数据管理活动。 SCCOP 此时热情地重新竞争以获得持续的资金 事实证明，这项活动对这个社区来说非常有益。